MARÍA DOLORES
CABALLERO BARRIGÓN
Investigadora en el periodo 1998-2022
Karolinska University Hospital
Estocolmo, SueciaPublicaciones en colaboración con investigadores/as de Karolinska University Hospital (11)
2023
2021
-
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Leukemia, Vol. 35, Núm. 12, pp. 3585-3588
2018
-
Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting
Medical Oncology, Vol. 35, Núm. 6
2017
-
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380
-
Unmet needs in the scientific approach to older patients with lymphoma
Haematologica
2015
-
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma
Leukemia, Vol. 29, Núm. 2, pp. 464-473
2013
-
Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: A prospective randomized trial from the lymphoma working party of the European Group for Blood and Marrow Transplantation
Journal of Clinical Oncology, Vol. 31, Núm. 13, pp. 1624-1630
2005
2003
-
Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow
Blood, Vol. 102, Núm. 8, pp. 3043-3051
-
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning
Leukemia, Vol. 17, Núm. 5, pp. 841-848
2002
-
Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia
Blood, Vol. 100, Núm. 12, pp. 3877-3886